Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'". - Okubo Y; Kobayashi S; Murakami M; Sano S; Kikuta N; Ouchi Y; Terui T (American journal of clinical dermatology, 2024)